<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cyanide poisoning</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cyanide poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cyanide poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shoma Desai, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark K Su, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Evan Schwarz, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cyanide is a mitochondrial toxin that is among the most rapidly lethal poisons known. Used in both ancient and modern times as a method of execution, cyanide causes death within minutes to hours of exposure. Though significant cyanide poisoning is uncommon, it must be recognized rapidly to ensure prompt administration of a lifesaving antidote and supportive treatment. A summary table to facilitate emergency management is provided (<a class="graphic graphic_table graphicRef65052" href="/z/d/graphic/65052.html" rel="external">table 1</a>).</p><p>This topic review will discuss the toxicity and management of cyanide poisoning. A general approach to the poisoned patient is found separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY AND SOURCES OF EXPOSURE</span><span class="headingEndMark"> — </span>Approximately 150 to 200 single-substance non-rodenticide cyanide exposures involving two to four fatalities are reported annually to United States regional poison control centers [<a href="#rid1">1-4</a>]. Also, approximately 150 to 200 administrations of cyanide antidotes (eg, <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a>, <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a>) are reported annually to United States regional poison control centers. Cyanide poisoning may result from a broad range of exposures (<a class="graphic graphic_table graphicRef76365" href="/z/d/graphic/76365.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fire-related</strong> – In industrialized countries, the most common cause of cyanide poisoning is domestic fires [<a href="#rid5">5</a>]. Cyanide can be liberated during the combustion of products containing both carbon and nitrogen. These products include wool, silk, polyurethane (insulation/upholstery), polyacrylonitriles (plastics), melamine resins (household goods), and synthetic rubber [<a href="#rid6">6-8</a>]. Vehicular fires can also expose victims to cyanide. Toxicologic evaluation of passengers following the 1985 explosion of a Boeing 737 during takeoff in Manchester, England, revealed that 20 percent of the 137 victims who escaped had dangerously elevated levels of carbon monoxide, while 90 percent had dangerously elevated levels of cyanide [<a href="#rid9">9</a>]. Overall, it is reported that significant levels of cyanide are present in up to 35 percent of all fire victims [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Industrial</strong> – Worldwide industrial consumption of cyanide is estimated to be 1.5 million tons per year, and occupational exposures account for a significant number of cyanide poisonings [<a href="#rid11">11</a>]. Metal extraction in mining, electroplating in jewelry production, photography, plastics and rubber manufacturing, hair removal from hides, and rodent pesticide and fumigants have all been implicated in cyanide poisonings. Skin contact with cyanide salts can result in burns, which allow for enhanced absorption of cyanide through the skin. The combination of cyanide salts and acid, as utilized in electroplating, results in the release of cyanide gas, which can lead to lethal inhalational exposures. Splashes of cyanide solutions can result in dermal as well as mucosal absorption [<a href="#rid5">5,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical</strong> – Cyanide exposures can result from alternative and standard medical treatments. Amygdalin (trade name Laetrile), a substance derived from apricot and peach kernels and introduced as an antineoplastic agent in the 1950s, can cause severe cyanide toxicity [<a href="#rid13">13-15</a>]. The drug is alleged to kill cancer cells selectively via its metabolite, hydrocyanic acid. Laetrile is available as a 500 mg oral tablet that contains 30 to 150 mg of amygdalin [<a href="#rid16">16</a>]. Intestinal beta-d-glucosidase digests the amygdalin, releasing hydrogen cyanide (HCN). This enzymatic reaction explains why only gastrointestinal exposure, in contrast to intravenous (IV) administration, results in toxicity [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">Sodium <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>, a medication used in the treatment of hypertensive emergencies, contains five cyanide groups per molecule. Toxic levels of cyanide may be reached in patients who receive prolonged infusions of sodium nitroprusside, in patients with chronic renal failure, or in pediatric patients [<a href="#rid17">17,18</a>]. Treatment for 3 to 10 hours with 5 to 10 mcg/kg per minute has resulted in fatalities [<a href="#rid19">19</a>]. Methods for preventing nitroprusside-induced cyanide poisoning include using silver foil on IV tubing (preventing light from decomposing the nitroprusside molecule), using maximal infusion rates of 2 mcg/kg per minute, and adding <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a> to the nitroprusside solution [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">"Drugs used for the treatment of hypertensive emergencies", section on 'Nitroprusside'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diet</strong> – The family Rosaceae, which includes the bitter almond, cherry laurel, apricot, plum, peach, pear, and apple, is responsible for many reported cyanide poisonings. These foods all contain cyanogenic glycosides, such as amygdalin, in their pits and seeds. The common (ie, sweet) almond does not cause cyanide intoxication. Other foods containing possible cyanogens include cassava root, bamboo shoots, and soy [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Ingestion of cyanide salts, such as potassium cyanide and sodium cyanide, continues to be a method of both suicide and homicidal/terrorist acts [<a href="#rid22">22</a>]. Miscellaneous exposure to cyanide may occur during illicit synthesis of phencyclidine, ingestion of acetonitrile (artificial nail polish remover), and cigarette smoking. Because of the natural cyanide found in tobacco, cigarette smokers have more than 2.5 times the mean whole blood cyanide level of nonsmokers (<a class="graphic graphic_table graphicRef65052" href="/z/d/graphic/65052.html" rel="external">table 1</a>) [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>In normal cellular metabolism, most adenosine triphosphate (ATP) is generated from oxidative phosphorylation. An important part of this process is the shuttling of electrons through the mitochondrial cytochrome complex (also known as the electron transport chain) (<a class="graphic graphic_figure graphicRef78699" href="/z/d/graphic/78699.html" rel="external">figure 1</a>).</p><p>Cyanide avidly binds to the ferric ion (Fe3+) of cytochrome oxidase a3, inhibiting this final enzyme in the mitochondrial cytochrome complex. When this enzyme's activity is blocked, oxidative phosphorylation ceases. The cell must then switch to anaerobic metabolism of glucose to generate ATP.</p><p>Anaerobic metabolism leads to the formation of lactic acid and the development of metabolic acidosis. Hydrogen ions produced by ATP hydrolysis are no longer consumed in aerobic ATP production, exacerbating this acidosis [<a href="#rid24">24</a>]. Serum bicarbonate decreases as it buffers excess acid, leading to an increased anion gap.</p><p>Despite an ample oxygen supply, cells cannot utilize oxygen because of their poisoned electron transport chain. This functional (or "histotoxic") hypoxia is particularly deleterious to the cardiovascular and central nervous systems (especially the basal ganglia).</p><p>A number of other mechanisms may exacerbate brain injury. Cyanide's nonspecific inhibition of antioxidants (such as catalase, glutathione reductase, and superoxide dismutase) results in the accumulation of toxic oxygen free radicals. Cyanide stimulates N-methyl-D-aspartate (NMDA) receptors, inducing apoptotic cell death. It also inhibits glutamic acid decarboxylase, the enzyme responsible for the formation of the inhibitory neurotransmitter gamma–aminobutyric acid (GABA) from glutamic acid. Consequently, cyanide increases the risk of seizures as GABA levels fall [<a href="#rid25">25-27</a>].</p><p>Although cyanide has a primary affinity for Fe3+, a small amount may bind to the ferrous ion (Fe2+) of hemoglobin, forming cyanohemoglobin, which is unable to transport oxygen, thereby further exacerbating tissue hypoxia [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H4"><span class="h1">KINETICS AND METABOLISM</span><span class="headingEndMark"> — </span>Cyanide is rapidly absorbed through the respiratory tract and mucous membranes, and it can also be absorbed through the gastrointestinal tract and skin [<a href="#rid28">28</a>]. Symptoms and signs of poisoning begin at blood cyanide concentrations of approximately 40 micromol/L [<a href="#rid29">29</a>]. Once absorbed, cyanide is quickly distributed in the body with an estimated volume of distribution of 1.5 L/kg. Approximately 60 percent is protein bound [<a href="#rid10">10</a>].</p><p>In vivo, cyanide metabolism and neutralization involve a number of mechanisms. The most important is the detoxification of cyanide via rhodanese. Rhodanese is an enzyme found abundantly in many tissues, particularly the liver and muscle [<a href="#rid28">28</a>]. Thiosulfate serves as a sulfur donor in the reaction catalyzed by rhodanese that converts cyanide to thiocyanate, a water-soluble molecule excreted in the urine [<a href="#rid5">5</a>].</p><p>A minor pathway for cyanide detoxification involves <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a>, the precursor to <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">vitamin B12</a>. Circulating hydroxocobalamin combines with cyanide to form cyanocobalamin, which is safely excreted in the urine. Finally, a small amount of unmetabolized cyanide is eliminated through urine, sweat, and expiration [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H616261319"><span class="h2">Acute exposure</span><span class="headingEndMark"> — </span>Clinical features of cyanide poisoning are dependent upon the route, source, and severity of exposure. Central nervous system and cardiovascular system dysfunction are most prominent. Symptoms and signs can include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system – Headache, anxiety, confusion, vertigo, loss of consciousness, seizures</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular – Initially tachycardia and hypertension, then bradycardia and hypotension, and dysrhythmias [<a href="#rid30">30</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory – Initial tachypnea then bradypnea, pulmonary edema</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal – Vomiting, abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Skin – Flushing ("cherry-red" color), cyanosis, irritant dermatitis (itching, erythema, edema, vesicles resulting from skin exposure) [<a href="#rid31">31</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Renal – Renal failure</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic – Hepatic necrosis</p><p class="bulletIndent1"><span class="glyph">●</span>Miscellaneous – Rhabdomyolysis, bright red venules seen on funduscopy, bitter almond or unusual odor [<a href="#rid30">30,32,33</a>]</p><p></p><p>Because cyanide poisoning impairs the utilization of oxygen by tissues, the venous oxyhemoglobin concentration is high, resulting in a bright red appearance to venous blood. On physical examination, this may manifest as a "cherry-red" color to the skin. However, this sign is present in a <strong>minority</strong> of cyanide-toxic patients. According to a review of 102 cases, a "cherry-red" skin color was found in only 11 percent of patients [<a href="#rid33">33</a>]. Normal skin color and cyanosis were more common skin findings.</p><p>The severity of symptoms depends on the route, dose, and duration of cyanide poisoning (<a class="graphic graphic_table graphicRef52242" href="/z/d/graphic/52242.html" rel="external">table 3</a>). After inhaling hydrogen cyanide (HCN), the victim may detect a bitter almond odor (discernible to approximately 60 percent of the population) [<a href="#rid32">32</a>]. Initially, inhalation of small amounts of HCN causes headache, anxiety, nausea, and a metallic taste [<a href="#rid12">12</a>]. In contrast, cyanogen chloride exposure predominantly results in eye and mucous membrane irritation and then pulmonary symptoms, namely bronchorrhea, cough, and dyspnea [<a href="#rid26">26</a>]. Inhalation of 100 ppm for 30 minutes or 300 ppm for five minutes is usually fatal [<a href="#rid12">12</a>].</p><p>While toxicity from inhalational exposure begins within seconds, toxicity from ingestion or dermal exposure is delayed from minutes to hours, depending on the extent of exposure. Ingestion of cyanide salts results in gastric irritation, frequently causing vomiting and abdominal pain [<a href="#rid19">19</a>].</p><p>Inhalational exposure to HCN gas at concentrations of approximately 200 parts per million will likely result in instantaneous death. However, lower concentrations over longer periods can also result in severe symptoms and death [<a href="#rid34">34</a>]. The average lethal dose from oral exposure is 1.52 mg/kg [<a href="#rid34">34</a>]. The lethal dermal exposure is estimated to be 100 mg/kg (<a class="graphic graphic_table graphicRef52242" href="/z/d/graphic/52242.html" rel="external">table 3</a>) [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Delayed sequelae</span><span class="headingEndMark"> — </span>Survivors of severe cyanide poisoning may develop delayed-onset Parkinsonism or other neurologic sequelae. The basal ganglia are particularly sensitive to cyanide toxicity [<a href="#rid32">32</a>]. Basal ganglia injury may be due to either direct cellular injury or secondary to hypoxic effects. Computed tomography (CT) and magnetic resonance imaging (MRI) of the brain may demonstrate radiologic changes several weeks after the exposure. Resolution of symptoms is variable, and treatment is supportive.</p><p class="headingAnchor" id="H7"><span class="h2">Chronic cyanide exposure</span><span class="headingEndMark"> — </span>Chronic cyanide exposure results in vague symptoms such as headache, dysgeusia (abnormal taste), vomiting, chest pain, abdominal pain, and anxiety [<a href="#rid12">12</a>]. There are at least three insidious syndromes associated with chronic, low-level cyanide exposure: tobacco amblyopia, tropical ataxic neuropathy, and Leber hereditary optic neuropathy.</p><p>Tobacco amblyopia occurs predominantly in male cigarette smokers and manifests as progressive visual loss. It may result from an inherent inability to detoxify cyanide, and symptoms may reverse following smoking cessation or <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> (Cyanokit) administration.</p><p>Tropical ataxic neuropathy is a demyelinating condition associated with excessive cassava consumption, usually in the poor and malnourished. The cassava plant contains a cyanogen, linamarin, which may be ingested if preparation of the plant is inadequate. Signs and symptoms of tropical ataxic neuropathy include paresthesias, ataxia, hearing loss, and optic atrophy. <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">Vitamin B12</a> deficiency may contribute to the condition. Cessation of dietary cassava and administration of vitamin B12 ameliorate symptoms.</p><p>Leber hereditary optic neuropathy is a rare, gradual loss of central vision that appears to be due to a defect in cyanide metabolism. A deficiency of rhodanese is one proposed mechanism.</p><p class="headingAnchor" id="H87269935"><span class="h1">LABORATORY EVALUATION</span></p><p class="headingAnchor" id="H87269998"><span class="h2">General testing</span><span class="headingEndMark"> — </span>Routine laboratory evaluation in the potentially poisoned patient should include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Point-of-care (eg, fingerstick) glucose concentration to rule out hypoglycemia as the cause of any alteration in mental status</p><p class="bulletIndent1"><span class="glyph">●</span>Acetaminophen and salicylate concentrations to rule out these common co-ingestions</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram (ECG) to rule out conduction system poisoning by drugs that affect the QRS or QTc intervals</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test in female patients of childbearing age</p><p></p><p class="headingAnchor" id="H87270005"><span class="h2">Specific testing</span><span class="headingEndMark"> — </span>Specific testing in cases of potential cyanide poisoning should also include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Basic blood chemistries (eg, Na+, Cl-, K+, HCO3-) and arterial or venous blood gas to assess for anion gap metabolic acidosis</p><p class="bulletIndent1"><span class="glyph">●</span>Blood lactate concentration to confirm hyperlactatemia</p><p class="bulletIndent1"><span class="glyph">●</span>Central venous blood gas, if possible, to assess venous-arterial partial pressure of oxygen (PO<sub>2</sub>) gradient</p><p class="bulletIndent1"><span class="glyph">●</span>Carboxyhemoglobin and methemoglobin levels (measured by <strong>co-oximetry</strong>), particularly if there is any concern for concomitant carbon monoxide exposure (eg, house or vehicle fire) or exposure to drugs that produce methemoglobinemia (<a class="graphic graphic_table graphicRef65052" href="/z/d/graphic/65052.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/z/d/html/322.html" rel="external">"Carbon monoxide poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/105477.html" rel="external">"Inhalation injury from heat, smoke, or chemical irritants"</a>)</p><p></p><p>Of note, treatment with <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> affects a number of laboratory tests. (See <a class="local">'Hydroxocobalamin'</a> below.)</p><p class="headingAnchor" id="H87270012"><span class="h3">Anion gap acidosis</span><span class="headingEndMark"> — </span>A severe metabolic acidosis with an increased anion gap is expected in cyanide poisoning. In addition to its inhibitory effects on cellular respiration, cyanide can induce cardiovascular collapse and seizures, which exacerbate anion gap metabolic acidosis. (See <a class="local">'Pathophysiology'</a> above.)</p><p class="headingAnchor" id="H87270019"><span class="h3">Lactate</span><span class="headingEndMark"> — </span>Cyanide-poisoned patients have an elevated blood lactate concentration. A retrospective study of 11 intensive care unit patients with cyanide poisoning found that plasma lactate concentrations correlated closely with the severity of cyanide toxicity [<a href="#rid35">35</a>]. There were significant inverse correlations between lactate and systolic blood pressure, respiratory rate, and arterial pH. In fact, lactate concentrations of 10 mmol/L or greater have been shown to be both sensitive and specific for cyanide poisoning in smoke inhalation victims [<a href="#rid36">36</a>]. Consequently, a normal serum lactate should lead the clinician to entertain other diagnoses, while serial lactate measurements can be used to monitor the progress of patients being treated for cyanide poisoning. Of note, a significant delay in laboratory processing of the patient's blood sample may cause an artificial elevation in lactate concentration.</p><p class="headingAnchor" id="H87270026"><span class="h3">Venous PO2</span><span class="headingEndMark"> — </span>A narrowing of the venous-arterial PO<sub>2</sub> gradient (ie, venous hyperoxia) may be seen in the cyanide-poisoned patient [<a href="#rid37">37</a>]. Cyanide inhibits cellular oxidative phosphorylation, resulting in a marked decrease in peripheral tissue oxygen extraction from the blood. This results in elevated central venous oxygenation. On examination, the skin may appear flushed and the venules in the retina bright red. Laboratory evaluation may reveal a decreased arterial–venous oxygen gradient. Clinicians should keep in mind that a decreased oxygen gradient is nonspecific and can result from other inhibitors of oxidative phosphorylation, such as carbon monoxide, hydrogen sulfide, and azides.</p><p class="headingAnchor" id="H87270033"><span class="h3">Cyanide concentration (level)</span><span class="headingEndMark"> — </span>Blood cyanide concentrations may be obtained for diagnostic confirmation, but results are not available in time to be clinically useful. Even when available, the results of direct testing may be unreliable as both proper storage conditions and prompt blood draws are required. Furthermore, blood cyanide concentrations do not correlate directly with survival. Nonetheless, blood cyanide concentrations of 0.5 to 1 mg/L (12 to 23 micromol/L) generally correlate with tachycardia and flushing, 1 to 2.5 mg/L (23 to 58 micromol/L) with obtundation, 2.5 to 3 mg/L (58 to 69 micromol/L) with coma, and greater than 3 mg/L (&gt;69 micromol/L) with death [<a href="#rid26">26</a>].</p><p>Cyantesmo test strips are colorimetric strips used in the testing of wastewater and during autopsies. One in vitro study assessed the ability of these strips to detect cyanide in simulated samples [<a href="#rid38">38</a>] and found they were accurate only at markedly elevated cyanide levels. Additional work is needed before this test can be considered for routine clinical use.</p><p>Given the limitations of cyanide concentration testing, antidotal treatment should be administered empirically based on the clinical presentation, and blood cyanide levels should serve mainly as confirmation.</p><p class="headingAnchor" id="H9"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Cyanide poisoning is an uncommon entity. Therefore, making the diagnosis requires that the clinician maintain a high index of suspicion based on the history and clinical presentation. Patients who are victims of fires or reported ingestions, are exposed at work, or have recently been treated with sodium <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> should all be considered potentially poisoned with cyanide. When a clear history is unavailable, clinicians should consider any patient with altered mental status and a metabolic acidosis of unknown etiology a possible victim of cyanide poisoning. Blood cyanide concentrations may not correlate with toxicity, and results are rarely available in time to guide the clinical management of acutely poisoned patients.</p><p class="headingAnchor" id="H87269650"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Carbon monoxide poisoning is similar to cyanide in presentation. (See  <a class="medical medical_review" href="/z/d/html/322.html" rel="external">"Carbon monoxide poisoning"</a>.)</p><p>Due to cyanide's wide range of possible symptoms and signs, the clinician must consider a number of potential diagnoses, including those listed below. Generally, the diagnosis is made based on a history of exposure and a consistent clinical presentation, since very few of these intoxicants have a rapidly available diagnostic test. If the diagnosis is in doubt, clinicians should seek assistance from a medical toxicologist or regional poison center. (See <a class="local">'Additional resources'</a> below.)</p><p>A patient with altered mental status, seizures, hypotension, and lactic acidosis may be poisoned with:</p><p class="bulletIndent1"><span class="glyph">●</span>Tricyclic antidepressants (see  <a class="medical medical_review" href="/z/d/html/295.html" rel="external">"Tricyclic antidepressant poisoning"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Isoniazid (see  <a class="medical medical_review" href="/z/d/html/481.html" rel="external">"Isoniazid: An overview"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Organophosphates (see  <a class="medical medical_review" href="/z/d/html/339.html" rel="external">"Organophosphate and carbamate poisoning"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Salicylates (see  <a class="medical medical_review" href="/z/d/html/329.html" rel="external">"Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Methemoglobin producing agents (see  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Strychnine (see  <a class="medical medical_review" href="/z/d/html/310.html" rel="external">"Strychnine poisoning"</a>)</p><p></p><p>A patient who suddenly collapsed after exposure to a gas may be poisoned with:</p><p class="bulletIndent1"><span class="glyph">●</span>Carbon monoxide (see  <a class="medical medical_review" href="/z/d/html/322.html" rel="external">"Carbon monoxide poisoning"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Hydrogen sulfide gas</p><p class="bulletIndent1"><span class="glyph">●</span>Phosphine</p><p class="bulletIndent1"><span class="glyph">●</span>Arsine (see  <a class="medical medical_review" href="/z/d/html/2020.html" rel="external">"Chemical terrorism: Rapid recognition and initial medical management"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Asphyxiants (eg, methane)</p><p></p><p>Also, exposure to cyanogen chloride can mimic exposure to any chemical irritant (eg, chlorine) [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H17"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Untreated cyanide poisoning is rapidly lethal. If clinical history and examination are suggestive of cyanide poisoning, antidotal therapy must be given immediately, barring any contraindications. Management should also include resuscitation and decontamination. A summary table to facilitate emergency management is provided (<a class="graphic graphic_table graphicRef65052" href="/z/d/graphic/65052.html" rel="external">table 1</a>). (See <a class="local">'Treatment with antidotes'</a> below.)</p><p>Care must be taken when evaluating victims of smoke inhalation. Carbon monoxide poisoned patients present similarly to those also poisoned by cyanide, and clinicians may focus on easily obtained carboxyhemoglobin levels, inadvertently neglecting to manage co-existent cyanide toxicity [<a href="#rid21">21</a>]. Cyanide toxicity should be considered in all smoke inhalation patients with two or more of the following: carbonaceous material in the oropharynx, neurologic dysfunction, metabolic acidosis on arterial blood gas, and serum lactate &gt;8 mmol/L [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/105477.html" rel="external">"Inhalation injury from heat, smoke, or chemical irritants"</a>.)</p><p>The recognition and management of cyanide poisoning can be difficult, and clinicians should seek assistance from a medical toxicologist or a regional poison center if they have any questions or concerns. (See <a class="local">'Additional resources'</a> below.)</p><p class="headingAnchor" id="H18"><span class="h2">Resuscitation</span><span class="headingEndMark"> — </span>First, clinicians must stabilize the patient's airway, breathing, and circulation. The patient's airway should be secured as necessary, and high-flow oxygen should be given regardless of pulse oximetry readings. Rescue breaths are contraindicated in cyanide poisoning due to the risk of exposure to the provider of cardiopulmonary resuscitation (CPR) [<a href="#rid19">19</a>]. Otherwise, CPR should be provided as per advanced cardiac life support protocols. (See  <a class="medical medical_review" href="/z/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/272.html" rel="external">"Adult basic life support (BLS) for health care providers"</a> and  <a class="medical medical_review" href="/z/d/html/6384.html" rel="external">"Pediatric basic life support (BLS) for health care providers"</a>.)</p><p>In unresponsive patients, point-of-care testing of serum glucose should be performed and, if hypoglycemic, supplemental dextrose should be administered. <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> should be administered if opioid toxicity is suspected. <a class="drug drug_general" data-topicid="9988" href="/z/d/drug information/9988.html" rel="external">Thiamine</a> is a benign antidote, and its administration should be considered, particularly in patients with a history of alcohol abuse. (See  <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">"Stupor and coma in adults"</a>.)</p><p>Seizures associated with cyanide poisoning are treated with benzodiazepines. Hypotension is treated with fluids and vasopressors as needed. Comorbid conditions and concurrent exposures are treated as necessary. Detailed discussions of the general management of the poisoned patient are provided separately. (See  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a> and  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Decontamination</span><span class="headingEndMark"> — </span>Patients poisoned by cyanide through inhalation or topical exposure must be rapidly removed from the source and their clothing taken off and appropriately discarded. In dermal exposures, wounds must be cleansed with soap and water to prevent further absorption. Rescuers should wear protective suits and respirators until proper decontamination is completed [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/345.html" rel="external">"Topical chemical burns: Initial evaluation and management"</a>.)</p><p>Gastrointestinal decontamination should be performed rapidly in cases of oral ingestion, as cyanide is quickly absorbed. Although laboratory studies have demonstrated that cyanide binds poorly to activated charcoal (AC), animal studies report decreased mortality among rats given AC after lethal potassium cyanide ingestions [<a href="#rid41">41</a>]. Therefore, we recommend administration of a single dose of AC (50 g in adults; 1 g/kg, up to 50 g maximum, in children). There is no evidence to support use of multiple doses of AC or cathartics such as <a class="drug drug_general" data-topicid="9580" href="/z/d/drug information/9580.html" rel="external">magnesium citrate</a> or <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a>. AC should be withheld in non-intubated patients with depressed mental status. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient"</a>.)</p><p>Orogastric lavage is not generally recommended. It should only be attempted if ingestion is recent and a large amount of cyanide is thought to be present in the upper gastrointestinal tract [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Antidotes: Concepts and available therapies</span><span class="headingEndMark"> — </span>If clinical history and examination are suggestive of cyanide poisoning, antidotal therapy must be given immediately, barring any contraindications. (See <a class="local">'Treatment with antidotes'</a> below.)</p><p>Antidotal treatment of cyanide poisoning involves three possible strategies: binding of cyanide, induction of methemoglobinemia, and use of sulfur donors.</p><p class="headingAnchor" id="H21"><span class="h3">Direct cyanide binding</span><span class="headingEndMark"> — </span>One strategy for cyanide neutralization involves direct binding of cyanide, preferably using <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> (Cyanokit). Dicobalt edetate also binds cyanide but can cause severe side effects.</p><p class="headingAnchor" id="H12183682"><span class="h4">Hydroxocobalamin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">Hydroxocobalamin</a>, a precursor of <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">vitamin B12</a>, contains a cobalt moiety that avidly binds to intracellular cyanide (with greater affinity than cytochrome oxidase), forming cyanocobalamin [<a href="#rid43">43</a>]. This molecule is stable and readily excreted in the urine. Because hydroxocobalamin acts rapidly, does not adversely affect tissue oxygenation, and is relatively safe, many investigators recommend it be used as the first-line agent in cyanide poisoning whenever it is available, and we concur with this approach [<a href="#rid44">44,45</a>].</p><p>The dose of <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> is 70 mg/kg (typical adult dose is 5 g) given intravenously (IV). This dose is effective for the majority of adult patients when cyanide exposure occurs by inhalation (eg, smoke inhalation). A second full dose may be given depending upon the severity of poisoning or the clinical response to treatment. Additional doses of hydroxycobalamin may be necessary in cases of severe poisoning (eg, oral ingestion) and for patients presenting <em>in extremis</em>. Although optimum pediatric dosing is not well established, some recommend 70 mg/kg IV (maximum dose 5 g) [<a href="#rid26">26</a>]. The half-life is 24 to 48 hours. In France, hydroxocobalamin is commonly used in conjunction with <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a>, a combination shown to be effective and safe in severe cyanide poisoning [<a href="#rid10">10,46-48</a>].</p><p><a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">Hydroxocobalamin</a>, when given at the recommended dose, may cause a temporary reddish discoloration of the skin, plasma, urine, and mucous membranes [<a href="#rid49">49,50</a>]. These changes last for approximately two to three days, altering the laboratory values of tests performed using co-oximetry or spectrophotometry. Blood tests that may be affected include creatinine, lactate, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), bilirubin, and magnesium [<a href="#rid21">21,51-53</a>]. Common urinalysis tests may also be affected (eg, glucose, protein, ketones, and leukocyte and erythrocyte counts).</p><p>As IV infusion of <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> interferes with co-oximetry measurements of total hemoglobin, carboxyhemoglobin, methemoglobin, and oxyhemoglobin, the assessment of smoke inhalation victims (who may suffer from simultaneous cyanide and carbon monoxide poisoning) is complicated by hydroxocobalamin administration [<a href="#rid54">54,55</a>].</p><p>Overall, <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> is safe and effective [<a href="#rid43">43,56</a>]. In a study of smoke inhalation victims who received hydroxocobalamin in the pre-hospital setting, survival was 74 percent (28/42) and 62 percent (8/13) in patients with blood cyanide concentrations of 1.7 to 4.3 mg/L (39 to 99 micromol/L) and &gt;4.3 mg/L (100 micromol/L, which is typically fatal), respectively [<a href="#rid46">46</a>]. In patients with confirmed cyanide toxicity and neurologic impairment, 51 percent (21/41) had neurologic improvement after hydroxocobalamin administration. All 15 patients who had cardiac arrest had hemodynamic improvement after hydroxocobalamin administration, but only 13 percent (2/15) survived to hospital discharge. In another study of smoke inhalation victims who received hydroxocobalamin in the pre-hospital setting, 42 percent (30/72) survived [<a href="#rid47">47</a>]. In 38 patients who had cardiac arrest, 21 (55 percent) had a return of spontaneous circulation, and in the 12 patients who were hypotensive, nine (75 percent) had improvement in blood pressure. One study of heavy cigarette smokers found that hydroxocobalamin decreased blood cyanide concentrations by 59 percent [<a href="#rid57">57</a>]. In a study of dogs administered cyanide, mortality was 21 percent after hydroxocobalamin 75 mg/kg and zero after hydroxocobalamin 150 mg/kg compared with 82 percent in dogs given placebo [<a href="#rid58">58</a>]. </p><p>In one study of <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> administration in adults, adverse effects from high doses included rash, headache, nausea, chest discomfort, decreased lymphocyte percentage, and dysphagia [<a href="#rid59">59</a>]. At the recommended dose, both transient hypertension and slowing of the heart rate have been reported [<a href="#rid10">10,52,57</a>].</p><p class="headingAnchor" id="H12183689"><span class="h4">Dicobalt edetate</span><span class="headingEndMark"> — </span>Dicobalt edetate is an IV chelator of cyanide, with a rapid onset of action, used primarily in the United Kingdom (it is not approved by the US Food and Drug Administration [FDA]). The dose is 20 mL of a 1.5% solution given over one minute. Although its use has been associated with multiple severe side effects including seizures, anaphylaxis, hypotension, and cardiac dysrhythmias [<a href="#rid5">5</a>]; a systematic review reports that this antidote is efficacious and that adverse effects may be less severe than previously thought [<a href="#rid60">60</a>]. Adverse effects appear to be more prominent when evidence of cyanide toxicity is mild or absent. Published cases of dicobalt edetate as an antidote for cyanide poisoning are limited [<a href="#rid60">60</a>], and additional experience with this antidote is needed to determine its safety and efficacy.</p><p class="headingAnchor" id="H22"><span class="h3">Induction of methemoglobinemia</span><span class="headingEndMark"> — </span>Another antidotal strategy involves the induction of methemoglobin. The formation of methemoglobin entails the oxidation of the ferrous (Fe2+) moiety in hemoglobin to the ferric (Fe3+) form. This provides an attractive alternative binding site for cyanide, in direct competition with the site on the cytochrome complex. When cyanide binds methemoglobin, a relatively less toxic cyanmethemoglobin is formed [<a href="#rid19">19</a>].</p><p>The induction of methemoglobinemia can be accomplished by the administration of either <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> or dimethylaminophenol (4-DMAP; not approved by the FDA). Nitrites should be avoided in pregnant patients. Sodium nitrite 300 mg is administered IV and typically induces a 15 to 20 percent methemoglobinemia [<a href="#rid59">59</a>], but the response can be quite variable. This degree of methemoglobinemia is tolerated by most patients. However, methemoglobin shifts the oxygen-hemoglobin dissociation curve to the left, further hindering oxygen delivery to tissues (<a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">figure 2</a>). Therefore, a decreased dose is used for patients with anemia because of potential adverse effects due to the formation of methemoglobin.</p><p>The appropriate dose of <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> given to patients with anemia can be adjusted according to the patient's hemoglobin. A medical toxicologist or regional poison center should be consulted for appropriate dosing. Approximate initial dosing is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 7 g/dL, dose is 0.19 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 8 g/dL, dose is 0.22 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 9 g/dL, dose is 0.25 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 10 g/dL, dose is 0.27 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 11 g/dL, dose is 0.30 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p></p><p>Patients receiving nitrites may develop hypotension and tachycardia [<a href="#rid19">19</a>]. These side effects are somewhat rate dependent. Arthralgias, myalgias, vomiting, and psychosis may also occur.</p><p>Prior to the availability of <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> (the preferred treatment for cyanide poisoning), in the United Sates, induction of methemoglobin was accomplished using the Cyanide Antidote Kit. The components of the now discontinued kit included <a class="drug drug_general" data-topicid="8767" href="/z/d/drug information/8767.html" rel="external">amyl nitrite</a>, <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a>, and <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a>. The Cyanide Antidote Kit has been replaced with <a class="drug drug_general" data-topicid="16469" href="/z/d/drug information/16469.html" rel="external">copackaged sodium nitrite and sodium thiosulfate</a> (Nithiodote), which may be needed if hydroxocobalamin is unavailable. Sodium nitrite and sodium thiosulfate are also available separately. Treatment with sodium nitrite is <strong>contraindicated</strong> in cases of concurrent carbon monoxide toxicity because it further impairs oxygen delivery. </p><p>In addition to inducing a methemoglobinemia, nitrites may provide benefit by causing vasodilation. Nitrites release <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">nitrous oxide</a>, a vasodilator, leading to increased blood flow to the liver and other organs, thereby enhancing the metabolism of cyanide. This proposed effect is supported by the success of other vasodilators in protecting the body from cyanide toxicity [<a href="#rid26">26,61</a>]. In an animal experiment, nitrite treatment alone provided a protective effect and tripled the dose of cyanide needed to cause death [<a href="#rid26">26</a>].</p><p>4-DMAP, an agent introduced in Germany, is another inducer of methemoglobin. 4-DMAP is given in a dose of 5 mL of a 5% solution IV over one minute. It is potent and rapidly acting, achieving peak levels of methemoglobin within five minutes of administration. The potency of 4-DMAP, which can require <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">methylene blue</a> to reverse the extent of methemoglobinemia, is problematic. Methylene blue, the recommended reversal agent for methemoglobinemia, should be avoided in the setting of cyanide poisoning because its use can release free cyanide [<a href="#rid62">62</a>]. Other potential adverse effects of 4-DMAP include reticulocytosis, nephrotoxicity, and hemolysis [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia"</a>.)</p><p>Of special note, patients who are victims of fires may be suffering from both carbon monoxide and cyanide toxicity. Carboxyhemoglobin causes the oxygen-hemoglobin dissociation curve to be shifted to the left, creating tissue hypoxia. In these patients, the induction of methemoglobinemia could be <strong>lethal</strong> [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/z/d/html/322.html" rel="external">"Carbon monoxide poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/105477.html" rel="external">"Inhalation injury from heat, smoke, or chemical irritants"</a>.)</p><p class="headingAnchor" id="H23"><span class="h3">Sulfur donors</span><span class="headingEndMark"> — </span>A third antidotal strategy involves maximizing the availability of sulfur donors for rhodanese, a ubiquitous enzyme that detoxifies cyanide by transforming it to thiocyanate. Thiocyanate is then renally excreted. The therapeutic sulfur donor of choice is <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a>.</p><p>In theory, a 3:1 ratio of <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a> to cyanide is required for complete detoxification. The standard adult dose of sodium thiosulfate is 50 mL of a 25% solution, or 12.5 g [<a href="#rid19">19,26</a>]. The onset of action may be slow (up to 30 minutes). Because thiocyanate levels of 10 mg/dL or higher may cause psychosis, arthralgias, vomiting, and myalgias, patients with renal failure may require hemodialysis to remove it from the bloodstream [<a href="#rid10">10</a>]. However, in most patients, sodium thiosulfate is safe and well tolerated.</p><p>In an animal experiment, thiosulfate treatment alone also provided a protective effect and quadrupled the dose of cyanide needed to cause death [<a href="#rid26">26</a>]. In combination, however, nitrites (lone treatment tripled the lethal dose of cyanide) and thiosulfate increased the dose of cyanide required to cause death 13-fold suggesting synergy between the two treatments.</p><p>The efficacy of dimethyl trisulfide (DMTS) for treating cyanide poisoning has been investigated in animal studies. DMTS is a plant-based sulfur donor that enhances cyanide clearance, has minimal side effects, and appears to be effective when administered intramuscularly [<a href="#rid64">64,65</a>]. A study of DMTS in vitro and in vivo (mouse model) revealed that DMTS penetrates the blood-brain barrier, which would afford protection against central nervous system damage [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H6019904"><span class="h3">Adjunct treatment with hyperbaric oxygen</span><span class="headingEndMark"> — </span>The results of two animal studies suggest that hyperbaric oxygen (HBO), used in combination with antidotal therapy, is an effective treatment for cyanide toxicity [<a href="#rid67">67,68</a>]. One study found that HBO may facilitate transport of cyanide from tissue to blood, theoretically enhancing detoxification [<a href="#rid67">67</a>]. The other reported improved respiratory status and a decreased surge in brain lactate with HBO therapy [<a href="#rid68">68</a>]. However, due to inconsistent findings in the literature overall, the use of HBO therapy in cyanide poisoning remains controversial. Further research and controlled studies in humans are needed.</p><p class="headingAnchor" id="H24"><span class="h2">Treatment with antidotes</span></p><p class="headingAnchor" id="H1606463002"><span class="h3">Overall recommendations and risks of nitrite therapy</span><span class="headingEndMark"> — </span>Cyanide poisoning is rare but requires decisive action when present. We recommend treatment with <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> whenever it is available.</p><p>In hospitals where <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> is unavailable, treatment with nitrites may be lifesaving. When the history and clinical findings strongly suggest cyanide toxicity, and hydroxocobalamin is not available, we recommend prompt treatment with both nitrites and <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a>. In such cases, the benefit of therapy outweighs the risks of methemoglobinemia. Patient assessment must be performed carefully, as induction of 20 to 30 percent methemoglobinemia in a patient who is critically ill from an etiology other than cyanide poisoning can cause significant patient morbidity or mortality. Methemoglobinemia can be harmful in anemic patients, who have little reserve. Nitrites should be avoided in pregnant patients and patients with carbon monoxide poisoning. (See <a class="local">'Induction of methemoglobinemia'</a> above.)</p><p class="headingAnchor" id="H25"><span class="h3">Suspected cyanide intoxication</span><span class="headingEndMark"> — </span>Availability of treatment varies by region and hospital. Immediately below is a series of antidotal management recommendations, based upon treatment availability, for patients with <strong>suspected</strong> cyanide intoxication:</p><p class="headingAnchor" id="H3735405436"><span class="h4">Hydroxocobalamin available</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients in locations where <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> is available, it is the preferred treatment. We recommend giving:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">Hydroxocobalamin</a> 5 g (adults) or 70 mg/kg IV (pediatric patients, maximum 5 g)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient does not have rapid clinical improvement after the initial dose, we recommend repeating the dose. A second dose can be given 10 to 15 minutes after completion of the first dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In extreme cases where no clinical improvement occurs after two doses of <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a>, it is reasonable to give a third dose of hydroxocobalamin <strong>and</strong> <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a> (25% solution) 50 mL (12.5 g) IV for adults or 1.65 mL/kg IV (412.5 mg/kg) IV for pediatric patients (maximum 12.5 g). In this situation, sodium thiosulfate should be administered via a <strong>separate</strong> IV line from the one used to give hydroxocobalamin.</p><p></p><p class="headingAnchor" id="H1649858243"><span class="h4">Hydroxocobalamin not available</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients without contraindication to nitrites and in locations where <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> is not available, we recommend treatment as follows [<a href="#rid61">61</a>]:</p><p></p><p class="bulletIndent1">Adult:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">Sodium nitrite</a> (3% solution) 10 mL IV (300 mg)<strong> </strong>at 2.5 to 5 mL per minute</p><p></p><p class="bulletIndent2"><strong>and</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">Sodium thiosulfate</a> (25% solution) 50 mL IV (12.5 g) immediately following <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> administration</p><p></p><p class="bulletIndent1">Pediatric: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">Sodium nitrite</a> (3% solution) 0.2mL/kg (6 mg/kg) IV at 2.5 to 5 mL per minute, not to exceed 10 mL (300mg)</p><p></p><p class="bulletIndent2"><strong>and</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">Sodium thiosulfate</a> (25% solution) 1.65 mL/kg (412.5 mg/kg) IV (maximum dose 12.5 g or 50 mL) given immediately following <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> administration</p><p></p><p class="headingAnchor" id="H1806968892"><span class="h4">Hydroxocobalamin not available and nitrites contraindicated</span><span class="headingEndMark"> — </span>For patients with contraindications to nitrites or with smoke inhalation (pending test results for carboxyhemoglobin) in locations where <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> is not available, we recommend <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a> monotherapy:</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">Sodium thiosulfate</a> (25% solution) 50 mL (12.5 g) IV for adults or 1.65 mL/kg IV (412.5 mg/kg) for pediatric patients (maximum 12.5 g)</p><p></p><p>Treatment with <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> is <strong>contraindicated</strong> in cases of potential carbon monoxide toxicity (eg, from a fire), until such toxicity has been excluded, because it further impairs oxygen delivery.</p><p class="headingAnchor" id="H857017759"><span class="h4">Only alternative therapies available</span><span class="headingEndMark"> — </span>In locations where 4-DMAP or dicobalt edetate is available, there are no contraindications to either drug, and neither <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> nor <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> is available, we recommend administering:</p><p class="bulletIndent1"><span class="glyph">●</span>4-DMAP (5% solution) 5 mL IV over one minute <strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If 4-DMAP is unavailable and <strong>only</strong> if cyanide poisoning is highly suspected or confirmed, give dicobalt edetate (1.5% solution) 20 mL IV over one minute</p><p></p><p class="headingAnchor" id="H27"><span class="h3">Empiric treatment for smoke inhalation</span><span class="headingEndMark"> — </span>Clinicians should consider the possibility of cyanide toxicity and maintain a low threshold for initiating treatment in victims of smoke inhalation. Frequently, victims of house fires have a depressed level of consciousness, which may be caused by cyanide, carbon monoxide, other inhaled or ingested toxins, traumatic shock, or head injury. The pathophysiology and general management of smoke inhalation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/105477.html" rel="external">"Inhalation injury from heat, smoke, or chemical irritants"</a>.)</p><p>We suggest that empiric treatment for cyanide toxicity be initiated in victims of smoke inhalation with an unexplained metabolic acidosis and increased blood lactate concentration or a low or declining end-tidal carbon dioxide (EtCO<sub>2</sub>) level. If these measurements are unavailable, we suggest treatment be initiated in any patient demonstrating a depressed level of consciousness, cardiac arrest, or hemodynamic decompensation [<a href="#rid69">69</a>].</p><p>The preferred antidotal treatment in this setting is identical to that for suspected cyanide poisoning:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">Hydroxocobalamin</a> 5 g (adults) or 70 mg/kg IV (pediatric patients, maximum 5 g)</p><p></p><p>Treatment with <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> is <strong>contraindicated</strong> in cases of potential carbon monoxide toxicity (eg, from a fire), until such toxicity has been excluded, because it further impairs oxygen delivery. (See <a class="local">'Induction of methemoglobinemia'</a> above.)</p><p>Blood lactate and EtCO<sub>2</sub> monitoring may provide useful information when determining management of smoke inhalation victims. Cyanide toxicity poisons mitochondria, forcing cells to use anaerobic metabolism. This results in a metabolic acidosis with a high lactate concentration and a compensatory drop in EtCO<sub>2</sub>. (See <a class="local">'Pathophysiology'</a> above and  <a class="medical medical_review" href="/z/d/html/273.html" rel="external">"Carbon dioxide monitoring (capnography)"</a>.) </p><p>Of note, <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> administration can interfere with carboxyhemoglobin measurements, causing the carboxyhemoglobin values obtained from co-oximetry to be inaccurate. (See  <a class="medical medical_review" href="/z/d/html/322.html" rel="external">"Carbon monoxide poisoning", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">PEDIATRIC CONSIDERATIONS</span><span class="headingEndMark"> — </span>The pathophysiology and clinical manifestations of acute cyanide poisoning are similar for children and adults [<a href="#rid70">70</a>]. However, pediatric patients appear to be more vulnerable to cyanide poisoning from smoke inhalation. This is thought to be due to their immature metabolism, lower body mass, and higher respiratory rate. (See <a class="local">'Clinical presentation'</a> above.)</p><p>As young children have higher concentrations of fetal hemoglobin and less methemoglobin reductase than adults, induced methemoglobinemia can reduce oxygen-carrying capacity to dangerously low levels. Therefore, <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> is the preferred treatment for cyanide intoxication, and it is considered safe in children [<a href="#rid71">71</a>]. Although optimum pediatric dosing is not well established, some recommend 70 mg/kg intravenously (IV; maximum 5 g) [<a href="#rid26">26,71</a>].</p><p>The major concern in children with cyanide poisoning involves management using <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> when <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> is unavailable. To avoid dangerously high methemoglobin levels, sodium nitrite should be dosed according to the patient's hemoglobin. A medical toxicologist or regional poison center should be consulted for dosing details and assistance with management. The approximate initial dose of sodium nitrite, to be given no faster than 5 mL per minute, is as follows [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 7 g/dL, dose is 0.19 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 8 g/dL, dose is 0.22 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 9 g/dL, dose is 0.25 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 10 g/dL, dose is 0.27 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 11 g/dL, dose is 0.30 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 12 g/dL, dose is 0.33 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 13 g/dL, dose is 0.36 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin 14 g/dL, dose is 0.39 mL/kg of 3% <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a></p><p></p><p>Point-of-care hemoglobin testing makes this approach easier to perform. In emergency departments where a rapid hemoglobin level is difficult to obtain, pediatric patients can be dosed based on their weight. The recommended pediatric dose of <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> is 0.2 mL/kg (6 mg/kg) of a 3% solution IV. The dose should not exceed 10 mL and should not be given at a rate greater than 5 mL per minute to avoid significant hypotension.</p><p><a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">Sodium thiosulfate</a> is given as 412.5 mg/kg IV (1.65 mL/kg of a 25% solution, up to a maximum of 12.5 g [50 mL]) [<a href="#rid61">61</a>]. For pediatric patients, we use a higher dose of sodium thiosulfate than what is included in United States prescribing information. Sodium thiosulfate appears to cause fewer adverse effects than <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> and is considered safe for use in children [<a href="#rid12">12,19</a>]. Gastrointestinal symptoms and localized burning at the injection site were noted in one volunteer study [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H106424559"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H3893362257"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H3990729619"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/135135.html" rel="external">"Society guideline links: Chemical terrorism"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lethality and emergency management table</strong> – Cyanide is among the most rapidly lethal poisons known. Tissue hypoxia is the key feature. A summary table to facilitate emergency management of cyanide exposure is provided (<a class="graphic graphic_table graphicRef65052" href="/z/d/graphic/65052.html" rel="external">table 1</a>). Clinicians should seek immediate assistance from a medical toxicologist or a regional poison center. (See <a class="local">'Additional resources'</a> above and <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sources of exposure</strong> – Cyanide poisoning may result from a broad range of exposures (<a class="graphic graphic_table graphicRef76365" href="/z/d/graphic/76365.html" rel="external">table 2</a>). In industrialized countries, the most common cause is domestic fires. Other causes include industrial exposure (eg, mining, electroplating, plastic manufacturing), standard and alternative medical treatments (eg, <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>, laetrile), and certain foods (eg, Rosaceae family). (See <a class="local">'Epidemiology and sources of exposure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Clinical features can vary widely with the route, duration, and intensity of exposure. Toxicity from parenteral exposure begins within seconds; toxicity from an ingestion or dermal exposure is delayed from minutes to hours (<a class="graphic graphic_table graphicRef52242" href="/z/d/graphic/52242.html" rel="external">table 3</a>). Central nervous system and cardiovascular system dysfunction are most prominent, but all organ systems can be affected. Symptoms and signs of acute toxicity and delayed sequela are described above. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1">Decreased utilization of oxygen by tissues causes the venous oxyhemoglobin concentration to be high, making venous blood appear bright red. Therefore, despite hypotension, apnea, and/or bradycardia, the patient does not appear cyanotic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – No definitive diagnostic test is readily available; diagnosis is made clinically. Victims of fires, patients with reported ingestions or recently treated with <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>, and industrial workers exposed to cyanide are all potentially cyanide poisoned. When a history is unavailable, clinicians should consider any patient with altered mental status and a severe anion gap metabolic acidosis of unknown etiology a possible cyanide poisoning. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/2352.html" rel="external">"Simple and mixed acid-base disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic testing</strong> – General laboratory evaluation of suspected cyanide poisoning should include point-of-care (eg, fingerstick) glucose, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and salicylate concentrations, electrocardiogram (ECG), and a pregnancy test in female patients of childbearing age. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1">In addition, the following studies should be obtained:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Basic chemistries (Na+, Cl-, K+, HCO3-) and arterial blood gas to assess for anion gap metabolic acidosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blood lactate to confirm lactic acidosis and assess severity of exposure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central venous blood gas, if possible, to assess for a diminished venous-arterial partial pressure of oxygen (PO<sub>2</sub>) gradient.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Carboxyhemoglobin and methemoglobin levels (measured by <strong>co-oximetry</strong>), particularly if there is any concern for concomitant carbon monoxide exposure (eg, house or vehicle fire) or exposure to drugs that produce methemoglobinemia (<a class="graphic graphic_table graphicRef51406" href="/z/d/graphic/51406.html" rel="external">table 4</a>). Intravenous (IV) infusion of <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> interferes with co-oximetry measurements of total hemoglobin, carboxyhemoglobin, methemoglobin, and oxyhemoglobin. (See <a class="local">'Laboratory evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/105477.html" rel="external">"Inhalation injury from heat, smoke, or chemical irritants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resuscitation</strong> – The clinician's first responsibility is to stabilize the patient's airway, breathing, and circulation. Mouth-to-mouth resuscitation is <strong>contraindicated</strong> due to the potential for provider exposure. Otherwise, cardiopulmonary resuscitation should be provided as per standard protocols. (See  <a class="medical medical_review" href="/z/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults"</a> and <a class="local">'Resuscitation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decontamination</strong> – Patients poisoned by inhalation or topical exposure must rapidly be extricated from the source and their clothing removed and appropriately discarded. In dermal exposures, wounds must be cleansed with soap and water to prevent further absorption. Rescuers should wear protective suits and respirators until decontamination is completed. (See <a class="local">'Decontamination'</a> above.)</p><p></p><p class="bulletIndent1">Gastrointestinal decontamination should be performed as quickly as possible in cases of oral ingestion. We recommend that a single dose of activated charcoal (AC) be administered (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>); the typical dose is 50 g in adults and 1 g/kg in children. There is no role for multiple-dose AC or cathartics (eg, <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a>). AC is not given to patients unable to protect their airway unless tracheal intubation is performed first. (See <a class="local">'Decontamination'</a> above and  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antidote treatment</strong> – Based upon treatment availability, we recommend antidotal therapy as outlined below. (See <a class="local">'Treatment with antidotes'</a> above.)</p><p></p><p class="bulletIndent1"><strong>Hydroxocobalamin</strong><strong> available</strong> – Whenever it is available, we recommend treatment with <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> for suspected cyanide poisoning (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The dose of hydroxocobalamin is 5 g (adults) or 70 mg/kg IV (pediatric patients, maximum 5 g). A second or third dose may be needed if the response to the first is inadequate. (See <a class="local">'Hydroxocobalamin'</a> above and <a class="local">'Hydroxocobalamin available'</a> above.) </p><p></p><p class="bulletIndent1"><strong>Hydroxocobalamin</strong><strong> not available</strong> – If <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> is not available and the patient is without contraindication to treatment with nitrites (eg, pregnancy, possible carbon monoxide poisoning), we recommend treatment with nitrites and <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a> (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). Dosing is as follows (see <a class="local">'Induction of methemoglobinemia'</a> above and <a class="local">'Hydroxocobalamin not available'</a> above): </p><p></p><p class="bulletIndent1">Adult: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">Sodium nitrite</a> (3% solution) 10 mL IV (300 mg)<strong> </strong>at 2.5 to 5 mL per minute</p><p></p><p class="bulletIndent2"><strong>and</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">Sodium thiosulfate</a> (25% solution) 50 mL IV (12.5 g) immediately following <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> administration</p><p></p><p class="bulletIndent1">Pediatric: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">Sodium nitrite</a> (3% solution) 0.2mL/kg (6 mg/kg)<strong> </strong>IV at 2.5 to 5 mL per minute; not to exceed 10mL (300 mg)</p><p></p><p class="bulletIndent2"><strong>and</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">Sodium thiosulfate</a> (25% solution) 1.65 mL/kg (412.5 mg/kg) IV (maximum dose 12.5 g or 50 mL) given immediately following <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> administration</p><p></p><p class="bulletIndent1"><strong>Hydroxocobalamin</strong><strong> not available and nitrites contraindicated</strong> – For patients with contraindications to nitrites or with smoke inhalation (pending test results for carboxyhemoglobin), in locations where <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">hydroxocobalamin</a> is not available, we recommend administering <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a> only (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). Dosing is as above. Treatment with <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">sodium nitrite</a> is <strong>contraindicated</strong> in cases of potential carbon monoxide toxicity (eg, from a fire), until such toxicity has been excluded, because it further impairs oxygen delivery. (See <a class="local">'Sulfur donors'</a> above and <a class="local">'Hydroxocobalamin not available and nitrites contraindicated'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report. Clin Toxicol (Phila) 2021; 59:1282.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Spyker DA, et al. 2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report. Clin Toxicol (Phila) 2019; 57:1220.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Spyker DA, et al. 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report. Clin Toxicol (Phila) 2018; 56:1213.</a></li><li><a class="nounderline abstract_t">Mégarbane B, Delahaye A, Goldgran-Tolédano D, Baud FJ. Antidotal treatment of cyanide poisoning. J Chin Med Assoc 2003; 66:193.</a></li><li><a class="nounderline abstract_t">Vogel SN, Sultan TR, Ten Eyck RP. Cyanide poisoning. Clin Toxicol 1981; 18:367.</a></li><li><a class="nounderline abstract_t">Bismuth C, Baud FJ, Djeghout H, et al. Cyanide poisoning from propionitrile exposure. J Emerg Med 1987; 5:191.</a></li><li><a class="nounderline abstract_t">Weger NP. Treatment of cyanide poisoning with 4-dimethylaminophenol (DMAP)--experimental and clinical overview. Fundam Appl Toxicol 1983; 3:387.</a></li><li><a class="nounderline abstract_t">Walsh DW, Eckstein M. Hydrogen cyanide in fire smoke: an underappreciated threat. Emerg Med Serv 2004; 33:160.</a></li><li><a class="nounderline abstract_t">Sauer SW, Keim ME. Hydroxocobalamin: improved public health readiness for cyanide disasters. Ann Emerg Med 2001; 37:635.</a></li><li><a class="nounderline abstract_t">Cummings TF. The treatment of cyanide poisoning. Occup Med (Lond) 2004; 54:82.</a></li><li class="breakAll">Sullivan, JB, Krieger, CR. Clinical Environmental Health and Toxic Exposures, 2nd, Lippincott Williams and Wilkins, Philadelphia 2001. p.705.</li><li><a class="nounderline abstract_t">Hall AH, Linden CH, Kulig KW, Rumack BH. Cyanide poisoning from laetrile ingestion: role of nitrite therapy. Pediatrics 1986; 78:269.</a></li><li><a class="nounderline abstract_t">O'Brien B, Quigg C, Leong T. Severe cyanide toxicity from 'vitamin supplements'. Eur J Emerg Med 2005; 12:257.</a></li><li><a class="nounderline abstract_t">Bromley J, Hughes BG, Leong DC, Buckley NA. Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C. Ann Pharmacother 2005; 39:1566.</a></li><li><a class="nounderline abstract_t">Litovitz TL, Larkin RF, Myers RA. Cyanide poisoning treated with hyperbaric oxygen. Am J Emerg Med 1983; 1:94.</a></li><li><a class="nounderline abstract_t">Gonzales J, Sabatini S. Cyanide poisoning: pathophysiology and current approaches to therapy. Int J Artif Organs 1989; 12:347.</a></li><li><a class="nounderline abstract_t">Vesey CJ, Cole PV, Simpson PJ. Cyanide and thiocyanate concentrations following sodium nitroprusside infusion in man. Br J Anaesth 1976; 48:651.</a></li><li class="breakAll">Bryson, PD. Comprehensive Review in Toxicology for Emergency Clinicians, 3rd, Taylor and Francis, Denver 1996. p.352.</li><li class="breakAll">The New York Poision Control Center. An Intensive Review Course in Clinical Toxicology, 2005. p.141.</li><li><a class="nounderline abstract_t">Huzar TF, George T, Cross JM. Carbon monoxide and cyanide toxicity: etiology, pathophysiology and treatment in inhalation injury. Expert Rev Respir Med 2013; 7:159.</a></li><li><a class="nounderline abstract_t">Hendry-Hofer TB, Ng PC, Witeof AE, et al. A Review on Ingested Cyanide: Risks, Clinical Presentation, Diagnostics, and Treatment Challenges. J Med Toxicol 2019; 15:128.</a></li><li><a class="nounderline abstract_t">Hall AH, Rumack BH. Clinical toxicology of cyanide. Ann Emerg Med 1986; 15:1067.</a></li><li><a class="nounderline abstract_t">Mizock BA. Lactic acidosis. Dis Mon 1989; 35:233.</a></li><li><a class="nounderline abstract_t">TURSKY T, SAJTER V. The influence of potassium cyanide poisoning on the gamma-aminobutyric acid level in rat brain. J Neurochem 1962; 9:519.</a></li><li><a class="nounderline abstract_t">Morocco AP. Cyanides. Crit Care Clin 2005; 21:691.</a></li><li><a class="nounderline abstract_t">Mohan A, Lee T, Sachdev P. Surviving acute cyanide poisoning: a longitudinal neuropsychological investigation with interval MRI. BMJ Case Rep 2014; 2014.</a></li><li class="breakAll">Amdur, MO, Doull J, et al. Casarett and Doull's Toxicology: The Basic Science of Poisons, 4th, McGraw-Hill, New York 1991. p.227.</li><li><a class="nounderline abstract_t">Geldner G, Koch EM, Gottwald-Hostalek U, et al. Report on a study of fires with smoke gas development : determination of blood cyanide levels, clinical signs and laboratory values in victims. Anaesthesist 2013; 62:609.</a></li><li><a class="nounderline abstract_t">Fortin JL, Desmettre T, Manzon C, et al. Cyanide poisoning and cardiac disorders: 161 cases. J Emerg Med 2010; 38:467.</a></li><li><a class="nounderline abstract_t">Rajashekar Ts, Okade R. Irritant contact dermatitis to accidental exposure of cyanide. Indian J Dermatol 2013; 58:162.</a></li><li class="breakAll">Greenberg, MI, Hamilton, et al. Occupational, Industrial, and Environmental Toxicology, Mosby, St. Louis 1997. p.165.</li><li><a class="nounderline abstract_t">Parker-Cote JL, Rizer J, Vakkalanka JP, et al. Challenges in the diagnosis of acute cyanide poisoning. Clin Toxicol (Phila) 2018; 56:609.</a></li><li class="breakAll">https://www.atsdr.cdc.gov/toxprofiles/TP.asp?id=72&amp;tid=19 (Accessed on December 24, 2018).</li><li><a class="nounderline abstract_t">Baud FJ, Borron SW, Mégarbane B, et al. Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning. Crit Care Med 2002; 30:2044.</a></li><li><a class="nounderline abstract_t">Baud FJ, Barriot P, Toffis V, et al. Elevated blood cyanide concentrations in victims of smoke inhalation. N Engl J Med 1991; 325:1761.</a></li><li><a class="nounderline abstract_t">Johnson RP, Mellors JW. Arteriolization of venous blood gases: a clue to the diagnosis of cyanide poisoning. J Emerg Med 1988; 6:401.</a></li><li><a class="nounderline abstract_t">Rella J, Marcus S, Wagner BJ. Rapid cyanide detection using the Cyantesmo kit. J Toxicol Clin Toxicol 2004; 42:897.</a></li><li><a class="nounderline abstract_t">Lawson-Smith P, Jansen EC, Hyldegaard O. Cyanide intoxication as part of smoke inhalation--a review on diagnosis and treatment from the emergency perspective. Scand J Trauma Resusc Emerg Med 2011; 19:14.</a></li><li><a class="nounderline abstract_t">Houston M, Hendrickson RG. Decontamination. Crit Care Clin 2005; 21:653.</a></li><li><a class="nounderline abstract_t">Lambert RJ, Kindler BL, Schaeffer DJ. The efficacy of superactivated charcoal in treating rats exposed to a lethal oral dose of potassium cyanide. Ann Emerg Med 1988; 17:595.</a></li><li><a class="nounderline abstract_t">Mokhlesi B, Corbridge T. Toxicology in the critically ill patient. Clin Chest Med 2003; 24:689.</a></li><li><a class="nounderline abstract_t">Thompson JP, Marrs TC. Hydroxocobalamin in cyanide poisoning. Clin Toxicol (Phila) 2012; 50:875.</a></li><li><a class="nounderline abstract_t">Dries DJ, Endorf FW. Inhalation injury: epidemiology, pathology, treatment strategies. Scand J Trauma Resusc Emerg Med 2013; 21:31.</a></li><li><a class="nounderline abstract_t">Dumestre D, Nickerson D. Use of cyanide antidotes in burn patients with suspected inhalation injuries in North America: a cross-sectional survey. J Burn Care Res 2014; 35:e112.</a></li><li><a class="nounderline abstract_t">Borron SW, Baud FJ, Barriot P, et al. Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation. Ann Emerg Med 2007; 49:794.</a></li><li><a class="nounderline abstract_t">Fortin JL, Giocanti JP, Ruttimann M, Kowalski JJ. Prehospital administration of hydroxocobalamin for smoke inhalation-associated cyanide poisoning: 8 years of experience in the Paris Fire Brigade. Clin Toxicol (Phila) 2006; 44 Suppl 1:37.</a></li><li><a class="nounderline abstract_t">Hall AH, Rumack BH. Hydroxycobalamin/sodium thiosulfate as a cyanide antidote. J Emerg Med 1987; 5:115.</a></li><li><a class="nounderline abstract_t">Borron SW, Baud FJ, Mégarbane B, Bismuth C. Hydroxocobalamin for severe acute cyanide poisoning by ingestion or inhalation. Am J Emerg Med 2007; 25:551.</a></li><li><a class="nounderline abstract_t">Heitzman J, Shen Q, Cazares J, Illoh O. Transfusion medicine illustrated: hydroxocobalamin-colored plasma. Transfusion 2009; 49:2555.</a></li><li><a class="nounderline abstract_t">Curry SC, Connor DA, Raschke RA. Effect of the cyanide antidote hydroxocobalamin on commonly ordered serum chemistry studies. Ann Emerg Med 1994; 24:65.</a></li><li><a class="nounderline abstract_t">DesLauriers CA, Burda AM, Wahl M. Hydroxocobalamin as a cyanide antidote. Am J Ther 2006; 13:161.</a></li><li><a class="nounderline abstract_t">Beckerman N, Leikin SM, Aitchinson R, et al. Laboratory interferences with the newer cyanide antidote: hydroxocobalamin. Semin Diagn Pathol 2009; 26:49.</a></li><li><a class="nounderline abstract_t">Lee J, Mukai D, Kreuter K, et al. Potential interference by hydroxocobalamin on cooximetry hemoglobin measurements during cyanide and smoke inhalation treatments. Ann Emerg Med 2007; 49:802.</a></li><li><a class="nounderline abstract_t">Livshits Z, Lugassy DM, Shawn LK, Hoffman RS. Falsely low carboxyhemoglobin level after hydroxocobalamin therapy. N Engl J Med 2012; 367:1270.</a></li><li><a class="nounderline abstract_t">Shepherd G, Velez LI. Role of hydroxocobalamin in acute cyanide poisoning. Ann Pharmacother 2008; 42:661.</a></li><li><a class="nounderline abstract_t">Forsyth JC, Mueller PD, Becker CE, et al. Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. J Toxicol Clin Toxicol 1993; 31:277.</a></li><li><a class="nounderline abstract_t">Borron SW, Stonerook M, Reid F. Efficacy of hydroxocobalamin for the treatment of acute cyanide poisoning in adult beagle dogs. Clin Toxicol (Phila) 2006; 44 Suppl 1:5.</a></li><li><a class="nounderline abstract_t">Uhl W, Nolting A, Golor G, et al. Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study. Clin Toxicol (Phila) 2006; 44 Suppl 1:17.</a></li><li><a class="nounderline abstract_t">Marrs TC, Thompson JP. The efficacy and adverse effects of dicobalt edetate in cyanide poisoning. Clin Toxicol (Phila) 2016; 54:609.</a></li><li class="breakAll">Holstege CP, Kirk MA. Cyanide and Hydrogen Sulfide. In: Goldfrank's Toxicologic Emergencies, 11th, Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS (Eds), McGraw-Hill, 2019. p.1684.</li><li><a class="nounderline abstract_t">Mokhlesi B, Leikin JB, Murray P, Corbridge TC. Adult toxicology in critical care: Part II: specific poisonings. Chest 2003; 123:897.</a></li><li class="breakAll">Rosen, P, Barkin, RM. Emergency Medicine:  Concepts and Clinical Practice, 3rd, Mosby, St. Louis 1992. p.2682.</li><li><a class="nounderline abstract_t">Hendry-Hofer TB, Witeof AE, Lippner DS, et al. Intramuscular dimethyl trisulfide: efficacy in a large swine model of acute severe cyanide toxicity. Clin Toxicol (Phila) 2019; 57:265.</a></li><li><a class="nounderline abstract_t">DeLeon SM, Downey JD, Hildenberger DM, et al. DMTS is an effective treatment in both inhalation and injection models for cyanide poisoning using unanesthetized mice. Clin Toxicol (Phila) 2018; 56:332.</a></li><li><a class="nounderline abstract_t">Kiss L, Bocsik A, Walter FR, et al. From the Cover: In Vitro and In Vivo Blood-Brain Barrier Penetration Studies with the Novel Cyanide Antidote Candidate Dimethyl Trisulfide in Mice. Toxicol Sci 2017; 160:398.</a></li><li><a class="nounderline abstract_t">Lawson-Smith P, Jansen EC, Hilsted L, et al. Effect of acute and delayed hyperbaric oxygen therapy on cyanide whole blood levels during acute cyanide intoxication. Undersea Hyperb Med 2011; 38:17.</a></li><li><a class="nounderline abstract_t">Lawson-Smith P, Olsen NV, Hyldegaard O. Hyperbaric oxygen therapy or hydroxycobalamin attenuates surges in brain interstitial lactate and glucose; and hyperbaric oxygen improves respiratory status in cyanide-intoxicated rats. Undersea Hyperb Med 2011; 38:223.</a></li><li><a class="nounderline abstract_t">Erdman AR. Is hydroxocobalamin safe and effective for smoke inhalation? Searching for guidance in the haze. Ann Emerg Med 2007; 49:814.</a></li><li><a class="nounderline abstract_t">Geller RJ, Barthold C, Saiers JA, Hall AH. Pediatric cyanide poisoning: causes, manifestations, management, and unmet needs. Pediatrics 2006; 118:2146.</a></li><li><a class="nounderline abstract_t">Mintegi S, Clerigue N, Tipo V, et al. Pediatric cyanide poisoning by fire smoke inhalation: a European expert consensus. Toxicology Surveillance System of the Intoxications Working Group of the Spanish Society of Paediatric Emergencies. Pediatr Emerg Care 2013; 29:1234.</a></li></ol></div><div id="topicVersionRevision">Topic 299 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34890263" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31752545" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30576252" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12854870" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antidotal treatment of cyanide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7016420" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cyanide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3429812" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cyanide poisoning from propionitrile exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6357924" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment of cyanide poisoning with 4-dimethylaminophenol (DMAP)--experimental and clinical overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15553543" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hydrogen cyanide in fire smoke: an underappreciated threat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11385334" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hydroxocobalamin: improved public health readiness for cyanide disasters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15020725" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The treatment of cyanide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15020725" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The treatment of cyanide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2942834" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cyanide poisoning from laetrile ingestion: role of nitrite therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16175068" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Severe cyanide toxicity from 'vitamin supplements'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014371" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6680611" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cyanide poisoning treated with hyperbaric oxygen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2674018" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cyanide poisoning: pathophysiology and current approaches to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/797397" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cyanide and thiocyanate concentrations following sodium nitroprusside infusion in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/797397" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cyanide and thiocyanate concentrations following sodium nitroprusside infusion in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/797397" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cyanide and thiocyanate concentrations following sodium nitroprusside infusion in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23547992" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Carbon monoxide and cyanide toxicity: etiology, pathophysiology and treatment in inhalation injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30539383" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A Review on Ingested Cyanide: Risks, Clinical Presentation, Diagnostics, and Treatment Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3526995" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical toxicology of cyanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2656163" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Lactic acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13994947" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The influence of potassium cyanide poisoning on the gamma-aminobutyric acid level in rat brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16168309" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cyanides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24648474" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Surviving acute cyanide poisoning: a longitudinal neuropsychological investigation with interval MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24648474" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Surviving acute cyanide poisoning: a longitudinal neuropsychological investigation with interval MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23917894" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Report on a study of fires with smoke gas development : determination of blood cyanide levels, clinical signs and laboratory values in victims.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185266" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cyanide poisoning and cardiac disorders: 161 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23716845" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Irritant contact dermatitis to accidental exposure of cyanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23716845" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Irritant contact dermatitis to accidental exposure of cyanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29417853" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Challenges in the diagnosis of acute cyanide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29417853" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Challenges in the diagnosis of acute cyanide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352039" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1944484" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Elevated blood cyanide concentrations in victims of smoke inhalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3147294" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Arteriolization of venous blood gases: a clue to the diagnosis of cyanide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15533029" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rapid cyanide detection using the Cyantesmo kit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21371322" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cyanide intoxication as part of smoke inhalation--a review on diagnosis and treatment from the emergency perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16168307" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Decontamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3377288" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The efficacy of superactivated charcoal in treating rats exposed to a lethal oral dose of potassium cyanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14710698" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Toxicology in the critically ill patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23163594" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hydroxocobalamin in cyanide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23597126" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Inhalation injury: epidemiology, pathology, treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23877146" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Use of cyanide antidotes in burn patients with suspected inhalation injuries in North America: a cross-sectional survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17481777" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16990192" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prehospital administration of hydroxocobalamin for smoke inhalation-associated cyanide poisoning: 8 years of experience in the Paris Fire Brigade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3295013" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hydroxycobalamin/sodium thiosulfate as a cyanide antidote.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17543660" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hydroxocobalamin for severe acute cyanide poisoning by ingestion or inhalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20163689" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Transfusion medicine illustrated: hydroxocobalamin-colored plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8010551" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effect of the cyanide antidote hydroxocobalamin on commonly ordered serum chemistry studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645433" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hydroxocobalamin as a cyanide antidote.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19292028" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Laboratory interferences with the newer cyanide antidote: hydroxocobalamin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17210205" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Potential interference by hydroxocobalamin on cooximetry hemoglobin measurements during cyanide and smoke inhalation treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23013097" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Falsely low carboxyhemoglobin level after hydroxocobalamin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18397973" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Role of hydroxocobalamin in acute cyanide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8492341" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16990189" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy of hydroxocobalamin for the treatment of acute cyanide poisoning in adult beagle dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16990190" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27352227" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The efficacy and adverse effects of dicobalt edetate in cyanide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27352227" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The efficacy and adverse effects of dicobalt edetate in cyanide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628894" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Adult toxicology in critical care: Part II: specific poisonings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628894" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Adult toxicology in critical care: Part II: specific poisonings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30306816" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Intramuscular dimethyl trisulfide: efficacy in a large swine model of acute severe cyanide toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28922956" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : DMTS is an effective treatment in both inhalation and injection models for cyanide poisoning using unanesthetized mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973547" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : From the Cover: In Vitro and In Vivo Blood-Brain Barrier Penetration Studies with the Novel Cyanide Antidote Candidate Dimethyl Trisulfide in Mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21384760" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effect of acute and delayed hyperbaric oxygen therapy on cyanide whole blood levels during acute cyanide intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21877551" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hyperbaric oxygen therapy or hydroxycobalamin attenuates surges in brain interstitial lactate and glucose; and hyperbaric oxygen improves respiratory status in cyanide-intoxicated rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17512866" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Is hydroxocobalamin safe and effective for smoke inhalation? Searching for guidance in the haze.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17079589" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pediatric cyanide poisoning: causes, manifestations, management, and unmet needs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24196100" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pediatric cyanide poisoning by fire smoke inhalation: a European expert consensus. Toxicology Surveillance System of the Intoxications Working Group of the Spanish Society of Paediatric Emergencies.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
